 MOUNTAIN VIEW, Calif., Dec. 06, 2021 GLOBE NEWSWIRE -- IGM Biosciences, Inc. Nasdaq: IGMS, a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that the Company will host a conference call and live audio webcast on Saturday, December 11, 2021, at 7:30 p.m. EST. The event will take place following an oral presentation featuring clinical data from the Phase 1 dose escalation study evaluating IGM-2323, the Companys novel CD20 x CD3 T cell engager IgM antibody for the treatment of B cell proliferative diseases, at the 63rd American Society of Hematology ASH Annual Meeting and Exposition. 